Media Kit

Media / Press Kit

About Enable Injections

Cincinnati-based Enable Injections is a global healthcare company developing and manufacturing drug delivery systems designed to improve the patient experience. Enable’s body-worn enFuse® delivers high-volume pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics.

 

Origin Story of Enable Injections

Enable was founded in 2010 by CEO Mike Hooven, who was working with Cincy Tech and Cincinnati Children’s Hospital Medical Center (CCHMC) to bring to market new technologies, when he learned about a concept for painless injections that was developed by a surgeon at CCHMC. Hooven utilized investments from CincyTech and selected individuals who had previously invested in Hooven’s companies to form Enable Injections.

Quick Stats:

  • ~200 employees
  • $215M in Series C funding, February 2022
  • Founded in 2010 by Mike Hooven

Current Public Partnerships Include:

  • Apellis Pharmaceuticals
  • CSL Behring
  • Roche/Genentech
  • Sanofi
  • Viridian Therapeutics

enFuse® Technology

Enable Injections’ enFuse® is a hands-free, hidden needle, large-volume drug delivery technology designed to subcutaneously (SC) deliver via constant pressure, which may offer potential clinical benefits. The enFuse® wearable drug delivery technology allows the patient to go about normal activities while the drug is being administered.

enFuse® Key Differentiators:

  • Flexibility: enFuse allows patients to receive treatment in a clinic or at home. enFuse also allows for high volume of delivery, from 4mL to 25mL, with a single device.
  • Mobility: enFuse wearable technology allows the patient to go about normal activities while administering medication in a hands-free manner.
  • Hidden Needle: The enFuse needle is hidden the entire time the patient handles the enFuse, from preparation to disposal of the delivery system.
  • Elastomeric technology: Our method of drug delivery is unique, through our elastomeric technology. Constant pressure vs flow rate allows the drug delivery to be responsive to the backpressure in the subcutaneous tissue, resulting in potential clinical benefits.

See the enFuse® in action:

EnywhereCare with enFuse® Vial Transfer System from Enable Injections on Vimeo.

 

Download Images:

Enable Injections logo

Enable Injections logo


Enable Injections logo black

Enable Injections logo, black


5-25-mL-enFuse-blue

enFuse device


EnableInjections-enFuse-Blue

enFuse, in hand


on-body-enFuse-Gray

enFuse, on-body


25-mL-enFuse with patient

Enable Injections enFuse, held by user


Enable Injections enFuse Vial Transfer System

Enable Injections enFuse Vial Transfer System


Enable Injections enFuse Syringe Transfer System

Enable Injections enFuse Syringe Transfer System


enable-injections-careers

Enable Injections Corporate Headquarters, Cincinnati, Ohio


Enable Injections CEO Mike Hooven with enFuse

Enable Injections CEO Mike Hooven with enFuse

 

 

Media Contact:

Jenn Beeson

[email protected]

 

Quick Links:

Press Releases

Awards & Recognition

Published Articles

Featured in:

Forbes

BI

Fierce

PharmaLetter

MarketWatch